VERAXA Biotech AG (NASDAQ: VRXA) has announced a significant milestone in its oncology pipeline: the VXA-222 bispecific antibody-drug conjugate (bsADC) program has moved beyond the discovery phase into the next stage of development. This progress follows the successful completion of the discovery portion of its collaboration with OmniAb Inc., which began in May 2025 (https://nnw.fm/nIprz). With the discovery work concluded, VERAXA will now focus on engineering the final bispecific ADC candidate, leveraging its proprietary antibody engineering, linker, and conjugation technologies.
The advancement of VXA-222 is notable because, unlike some of VERAXA's other programs, it is not based on the company's BiTAC platform. Instead, it relies on the company's core expertise in antibody engineering and conjugation, which are critical for developing effective ADCs. This program is among VERAXA's most advanced development candidates, highlighting the company's ability to diversify its pipeline beyond its proprietary platform.
In parallel with the VXA-222 progress, VERAXA has expanded its intellectual property portfolio with its first BiTAC-related patent filings, as well as additional patents supporting conjugation chemistry, payloads, and antibody technologies. The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries. Newly filed applications are expected to extend protection into at least 2047, providing long-term exclusivity for its innovations.
This dual advancement is significant for VERAXA as it continues to build a diversified oncology pipeline that includes bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats aimed at difficult-to-treat cancers. The expansion of the patent portfolio not only protects the company's current programs but also establishes a strong foundation for future developments.
The importance of this news lies in VERAXA's strategic positioning in the competitive field of cancer therapeutics. By advancing VXA-222 and strengthening its IP, the company demonstrates progress in its mission to design novel cancer therapies. The patent expansion, in particular, provides a competitive edge by safeguarding its innovations, which is crucial for attracting potential partners and investors. As VERAXA moves VXA-222 into preclinical validation, the coming months will be critical in determining the program's viability and potential impact on patient outcomes.
